Signal transduction and apoptosis pathways as therapeutic targets.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Progress in molecular and subcellular biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-540-74264-7_15PMID 15171618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.

  2003cited by this paper
• Rho GTPases in human carcinogenesis: a tale of excess

  2003cited by this paper
• Signal transduction--directed cancer treatments.

  2003cited by this paper
• Distinct requirements for Ras oncogenesis in human versus mouse cells.

  2002cited by this paper
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002cited by this paper
• Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

  2002cited by this paper
• Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

  2002cited by this paper
• New approaches to the treatment of myelodysplasia.

  2002cited by this paper
• Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment.

  2002cited by this paper
• Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.

  2002cited by this paper
• Thalidomide as an anti‐cancer agent

  2002cited by this paper
• Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

  2002cited by this paper
• Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Apoptosis A Link between Cancer Genetics and Chemotherapy

  2002cited by this paper
• Gene therapy for liver metastases.

  2002cited by this paper
• Therapeutic exploitation of the p53 pathway.

  2002cited by this paper
• Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer

  2002cited by this paper
• Targeting the cell cycle for cancer therapy

  2002cited by this paper
• Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

  2002cited by this paper
• Tyrosine kinase inhibitors: A clinical perspective

  2002cited by this paper
• Phase II trial of thalidomide in renal-cell carcinoma.

  2002cited by this paper
• Actin' up: RhoB in cancer and apoptosis

  2001cited by this paper
• A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death.

  2001cited by this paper
• Commuting the death sentence: how oocytes strive to survive

  2001cited by this paper
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

  2001cited by this paper
• Angiogenesis inhibitors in the treatment of lung cancer.

  2001cited by this paper
• Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Searching new targets for anticancer drug design: the families of Ras and Rho GTPases and their effectors.

  2001cited by this paper
• Regulation and function of the p53 tumor suppressor protein.

  2001cited by this paper
• Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo *

  2001cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• The expanding role of mitochondria in apoptosis.

  2001cited by this paper
• AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.

  2001cited by this paper
• Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.

  2001cited by this paper
• Æ-941 (Neovastat®): a novel multifunctional antiangiogenic compound

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Apoptotic pathways: paper wraps stone blunts scissors.

  2000cited by this paper
• Checkpoints: How to activate p53

  2000cited by this paper
• Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

  2000cited by this paper
• Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

  2000cited by this paper
• Targeting gene expression to tumor cells with loss of wild-type p53 function

  2000cited by this paper
• How to activate p53.

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• Apoptosis in cancer.

  2000cited by this paper
• Chemosensitisation of malignant melanoma by BCL2 antisense therapy.

  2000cited by this paper
• A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

  2000cited by this paper
• CD95's deadly mission in the immune system

  2000cited by this paper
• Preclinical and clinical development of cyclin-dependent kinase modulators.

  2000cited by this paper
• Antisense raf Oligodeoxyribonucleotide Is a Radiosensitizer In Vivo

  1999cited by this paper
• INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

  1999cited by this paper
• The role of p53 in tumour suppression: lessons from mouse models

  1999cited by this paper
• Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

  1999cited by this paper
• Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

  1999cited by this paper
• Potential roles for p53 in nucleotide excision repair.

  1999cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.

  1998cited by this paper
• The p53 Network*

  1998cited by this paper
• Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

  1997cited by this paper
• Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Identification of redox/repair protein Ref-1 as a potent activator of p53.

  1997cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.

  1997cited by this paper
• Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer.

  1997cited by this paper
• A model for p53-induced apoptosis

  1997cited by this paper
• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

  1996cited by this paper
• Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

  1996cited by this paper
• Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

  1996cited by this paper
• Role for c-Abl tyrosine kinase in growth arrest response to DNA damage

  1996cited by this paper
• The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.

  1996cited by this paper
• Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

  1995cited by this paper
• A novel form of Epstein-Barr virus latency in normal B cells in vivo.

  1995cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression

  1995cited by this paper
• Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

  1995cited by this paper
• Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

  1994cited by this paper
• Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

  1993cited by this paper
• Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.

  1992cited by this paper
• The type 1 (EGFR-related) family of growth factor receptors and their ligands.

  1992cited by this paper
• Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

  1992cited by this paper
• Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.

  1991cited by this paper
• Participation of p53 protein in the cellular response to DNA damage.

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

  1988cited by this paper
• The epidermal growth factor receptor as a multifunctional allosteric protein.

  1988cited by this paper
• Growth factor receptor tyrosine kinases.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The EGF receptor: structure, regulation and potential role in malignancy.

  1985cited by this paper
• Epidermal growth factor

  1972cited by this paper

• No citing papers are available for this paper.